VTRS|Analyst Targets
VTRS|Company Info
VTRS|Insider Trading
VTRS|Fundamentals
VTRS|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $0.64 | - | - |
| Q2'26 | $0.61 | $0.69 | +12.6% |
| Q1'26 | $0.61 | $0.59 | -3.4% |
| Q4'25 | $0.55 | $0.57 | +3.4% |
| Q3'25 | $0.62 | $0.67 | +8.5% |
| Q2'25 | $0.56 | $0.62 | +11.6% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $3.9B | - | - |
| Q2'26 | $3.8B | $3.8B | +0.1% |
| Q1'26 | $3.4B | $3.5B | +2.7% |
| Q4'25 | $3.3B | $3.7B | +10.7% |
| Q3'25 | - | $3.8B | - |
| Q2'25 | - | $3.6B | - |
VTRS|Monthly Returns
Market Data
VTRS Stock Snapshot
- Market cap
- 19.92B
- Day range
- $17.20 – $17.69
- News sentiment
- 70/100 · Bullish
- Analyst target
- $19.70 (+14.2%)
- Consensus
- Buy · 18 analysts
The signal on VTRS is bullish: price action is confirming the underlying trend, not fighting it. Institutional coverage is thorough here, so shifts in analyst expectations show up in price quickly.
Reverse DCF
What growth is priced into VTRS?
At today's price, Viatris Inc. needs to grow free cash flow about -6.1% a year for the next 10 years to justify its valuation at a 6.60% cost of capital. Over its actual history it has compounded free cash flow at 3.9% a year, so the market is asking for 10.0 percentage points below its own delivered rate. On that basis VTRS looks priced below what its own growth record supports.
- Implied FCF growth
- -6.1%
- Historical FCF CAGR
- 3.9%
- Growth gap
- -10.0 pts
- Verdict
- CHEAP
- Discount rate (WACC)
- 6.60%
- Beta
- 0.80
Behaviour On Record
What VTRS's own history says about today's numbers
- Realized volatility (21d)
- 23.8% 20th pct
- Below its peak
- -77.2%
- vs 200-day average
- +11.4%
- Up days (1y)
- 54%
Viatris Inc. is currently running 23.8% annualised volatility over the last 21 sessions. Measured against VTRS's own 13 years of daily returns rather than a market-wide average, that is the 20th percentile — unusually subdued by its own history, against a typical reading of 30.3%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
VTRS is trading -77.2% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -39.1%, and the deepest was -48.1% in 2015. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.
Price sits +11.4% from its 200-day moving average. Against every other day in its history, that gap ranks at the 84th percentile — a wider gap than this stock usually carries. Over the past year VTRS closed higher on 54% of sessions, and it is currently 2 sessions into a falling streak.
On October specifically: over 13 years of records, VTRS finished the month higher 7 of 13 times, with a median return of +0.7% and an average of +1.4%. Its strongest month historically has been November at +4.9% on average, its weakest March at -5.4%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: VTRS has opened more than 2% away from the prior close in 148 of 3,267 sessions (4.5% of the time), with the largest gaps running +9.8% and -5.7%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
Across the last 3 dated reports on file, VTRS moved an average of 1.5% in the session after earnings, closing higher 1 of those 3 times, with a median move of -1.5% and a largest of -2.0%.
All figures computed from 3,268 daily closes between 2013-10-15 and 2026-10-13, split-adjusted, recomputed daily. Percentiles are against VTRS's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of VTRS's sector?
Viatris Inc. sits in the Health Care sector, currently ranked 5th of 12 GICS sectors by relative-strength rotation score (improving).
- Sector rank
- #5 of 12
- Sector state
- Improving
- Sector rotation score
- 64
Analyst Rating Changes
Are analysts turning bullish or bearish on VTRS?
UBS most recently reiterated its rating on Viatris Inc. to Buy on Oct 5, 2026 with a price target of $26 (from $23). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.
- Latest action
- UBS — Buy
- 90-day upgrades
- 0
- 90-day downgrades
- 0
- Net rating momentum
- 0
Earnings Release, Scored
What did Viatris Inc.'s latest earnings release say?
Most important lines
- 1
Our strong first-half results give us the confidence to raise our full-year guidance.
Guidance raisedNew this quarter - 2
In August, the Company signed a definitive agreement to sell the global product rights for Tyrvaya to Harrow, Inc., a leading provider of ophthalmic disease management solutions in North America, for an upfront payment of $30 million and an additional $70 million in commercial contingent milestone payments.
New this quarter - 3
The loss in the second quarter of 2026 was primarily driven by a non-cash charge of $177.8 million related to the planned sale of the product rights for Tyrvaya ® and the write down of that intangible asset to fair value, less cost to sell.
New this quarter
Peers & ETF holders
VTRS peers & ETF holders
Drug Manufacturers - Specialty & GenericMarket cap · today
- VTRSYou're here$19.9B0.00%
- ZTSZoetis Inc.$30.9B+0.68%
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| Vanguard Group Inc | ▼ Sell | 138,179,864 | 11.96% | $1.72B | 2026-01-29 |
| FMR LLC (Fidelity) | ▲ Buy | 96,662,102 | 8.37% | $1.53B | 2026-08-13 |
| BlackRock, Inc. | ▲ Buy | 86,019,468 | 7.45% | $1.37B | 2026-08-07 |
| Davis Selected Advisers | ▼ Sell | 75,232,254 | 6.51% | $1.19B | 2026-08-11 |
| Geode Capital Management, LLC | ▲ Buy | 32,807,906 | 2.84% | $520.10M | 2026-08-12 |
| Invesco Ltd. | ▼ Sell | 20,771,275 | 1.80% | $329.85M | 2026-08-14 |
| Morgan Stanley | ▼ Sell | 15,128,899 | 1.31% | $240.25M | 2026-08-13 |
| Goldman Sachs Group Inc | ▼ Sell | 13,564,872 | 1.17% | $215.41M | 2026-08-14 |
| Northern Trust Corp | ▼ Sell | 10,038,691 | 0.87% | $159.41M | 2026-08-13 |
| Glenview Capital Management, LLC | ▲ Buy | 9,877,409 | 0.86% | $156.85M | 2026-08-14 |
| JPMorgan Chase & Co | ▲ Buy | 7,322,267 | 0.63% | $119.69M | 2026-08-12 |
| Bank of America Corp | ▲ Buy | 7,356,708 | 0.64% | $116.82M | 2026-08-14 |
| AQR Capital Management LLC | ▼ Sell | 4,694,966 | 0.41% | $74.56M | 2026-08-14 |
| Gotham Asset Management, LLC | ▼ Sell | 4,374,683 | 0.38% | $69.47M | 2026-08-14 |
| Citigroup Inc | ▲ Buy | 4,360,444 | 0.38% | $69.24M | 2026-08-03 |
| Norges Bank | ▼ Sell | 3,822,744 | 0.33% | $60.71M | 2026-08-12 |
| Man Group plc | ▼ Sell | 3,523,052 | 0.31% | $55.95M | 2026-08-14 |
| Bridgewater Associates, LP | ▲ Buy | 1,698,341 | 0.15% | $26.97M | 2026-08-14 |
| Moore Capital Management, LP | ▲ Buy | 1,430,654 | 0.12% | $22.72M | 2026-08-14 |
| Wells Fargo & Company | ▲ Buy | 1,175,495 | 0.10% | $18.67M | 2026-08-14 |
| AllianceBernstein L.P. | ▲ Buy | 1,233,234 | 0.11% | $16.66M | 2026-08-14 |
| Prudential Financial Inc | ▲ Buy | 849,694 | 0.07% | $13.49M | 2026-08-12 |
| Adage Capital Partners GP, L.L.C. | ▲ Buy | 843,736 | 0.07% | $13.40M | 2026-08-14 |
| Marshall Wace, LLP | ▼ Sell | 839,820 | 0.07% | $13.34M | 2026-08-13 |
| D. E. Shaw & Co., Inc. | ▼ Sell | 791,371 | 0.07% | $12.57M | 2026-08-14 |
| Member | Chamber | State | Type | Amount | Traded | Filed |
|---|---|---|---|---|---|---|
| Gilbert Cisneros | House | CA31 | ▲ Buy | $1K - $15K | 2025-11-18 | 2025-12-15 |
| Rob Bresnahan | House | PA08 | ▼ Sell | $1K - $15K | 2025-04-08 | 2025-05-08 |
| Gilbert Cisneros | House | CA31 | ▼ Sell | $1K - $15K | 2025-03-31 | 2025-04-07 |
| Rob Bresnahan | House | PA08 | ▲ Buy | $1K - $15K | 2025-02-25 | 2025-03-27 |
| Tommy Tuberville | Senate | AL | ▼ Sell | $1K - $15K | 2022-08-01 | 2022-09-15 |
| Tommy Tuberville | Senate | AL | ▼ Sell | $1K - $15K | 2022-01-13 | 2022-02-14 |